Financial Health of AbbVie Inc. in Q1 2024

A Snapshot of AbbVie's Balance Sheet

AbbVie Inc., a global biopharmaceutical company, has shown a robust financial performance in the first quarter of 2024. The company's total assets stand at approximately $148.9 billion, with total liabilities amounting to around $140.8 billion. This results in a total equity of $8.05 billion, reflecting a solid financial foundation.

Key Metrics and Insights

• Total Assets: AbbVie's total assets are valued at $148.9 billion, with a significant portion attributed to intangible assets ($62.2 billion) and goodwill ($33.4 billion).
• Liabilities: The company's total liabilities are $140.8 billion, with long-term debt making up $63.8 billion. Notably, short-term debt is $10.2 billion.
• Equity: Despite the high liabilities, AbbVie maintains a total equity of $8.05 billion, indicating a stable financial position.
• Cash Reserves: AbbVie holds $18.1 billion in cash and cash equivalents, ensuring liquidity for operational needs.

Financial Ratios

• Debt-to-Equity Ratio: The debt-to-equity ratio is approximately 9.2, highlighting the company's reliance on debt financing.
• Current Ratio: With total current assets of $38.9 billion and total current liabilities of $41.5 billion, the current ratio is 0.94, indicating a slight liquidity challenge.

Conclusion

AbbVie Inc.'s financial metrics for Q1 2024 reveal a company with substantial assets and a strong equity base, despite high debt levels. The company's significant cash reserves and valuable intangible assets position it well for future growth and stability.